ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1684	National Cancer Institute	Html	en	Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Gastrointestinal Stromal Tumors	imatinib response 0.41821 higher-dose imatinib mesylate 0.47787 imatinib therapy. 0.433313 Demetri GD 0.381845 TKI imatinib mesylate 0.494206 KIT receptor tyrosine 0.378346 KIT exon 0.370015 gastrointestinal stromal cell 0.41709 KIT-expressing primary GIST 0.416866 small GIST tumors 0.5328 gastrointestinal stromal tumour 0.414558 patients 0.452898 primary GIST 0.421404 complete gross resection 0.401005 adjuvant imatinib 0.525629 gastrointestinal stromal tumor 0.540132 GIST morphology 0.406777 high-dose imatinib 0.421288 stromal tumor resection 0.405207 tyrosine kinase inhibitor 0.379801 GIST patients 0.413735 et al. 0.374864 GIST resection 0.432449 tyrosine kinase 0.423999	metastatic GIST 0.418294 imatinib resistance 0.431916 gastrointestinal stromal tumors 0.903165 recurrent GIST 0.424604 imatinib mesylate 0.752767 imatinib therapy 0.416737 tyrosine kinase inhibitors 0.389426 imatinib ultimately experience 0.466343 GIST range 0.411206 imatinib-resistant GIST 0.405402 GIST 0.738771 Abstract 0.430607 common mesenchymal tumors 0.369545 Clin Oncol 0.46383 imatinib doses 0.430101 imatinib arm 0.426642 Familial GIST 0.424119 indolent GIST 0.42682 gastrointestinal stromal tumours 0.756245 imatinib era 0.421816 inoperable GIST 0.404394 new GIST cases 0.474154 advanced incurable GIST 0.424115 postoperative adjuvant imatinib 0.452036	CLICK HERE
1703	National Cancer Institute	Html	en	Tumor Grade	A fact sheet that discusses tumor grade and its role in prognosis. Explains concepts like normal cell biology and cell differentiation.	Gleason score 0.401724 NCI fact sheet 0.404685 lower grade 0.405507 tissue organization 0.400496 better prognosis 0.354968 tumor tissue 0.703634 type-specific grading systems 0.412132 tumor type 0.491464 cancer cells 0.405656 biopsied tissue 0.413701 Gleason scores 0.355221 primary brain tumors 0.42294 tumor size 0.501863 abnormal-looking cells 0.400459 Nottingham grading 0.360235 higher-grade cancer 0.364598 tumor cells 0.631844 normal cells 0.49423 nearby lymph nodes 0.408457 tumor grade 0.785451 regional lymph node 0.409603 secondary pattern 0.388809 breast tumors 0.384185 Scarff-Bloom-Richardson grading 0.361738	normal tissue structures 0.487646 primary pattern 0.353415 microscopic examination 0.353649 breast cancer 0.39308 biopsy samples 0.354483 Staging page 0.357155 microscopic appearance 0.359178 different types 0.358151 tumors 0.490957 prostate cancer 0.440387 cancer staging 0.368981 slower rate 0.360886 American Joint Committee 0.39399 tumor 0.981653 tumor grades 0.501473 common tissue pattern 0.44497 cancer 0.557882 total score 0.354108 soft tissue sarcoma 0.443518 prostate cancers 0.367392 Gleason scoring 0.35738 tumor tissue look 0.635152 cancer stage 0.457333	CLICK HERE
1843	National Cancer Institute	Html	es	Tratamiento del cáncer de vesícula biliar (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vesícula biliar.	gemcitabina vs 0.562266 Compton CC 0.670359 Tsukada K 0.846255 Surg Oncol Clin 0.680412 situ carcinoma 0.687891 accessed october 0.566163 Trimodality therapy 0.564056 American Cancer Society 0.950284 7th ed 0.669585 Estadio II–IV 0.581785 Chijiiwa K 0.675106 Surgical indications 0.564187 Instituto Nacional 0.7169 Primary carcinoma 0.710358 clasificación patológica t2 0.60477 Uchida K 0.58031 enfermedad t2 0.580737 Arch Surg 0.626332 Inapparent carcinoma 0.891598 determinados pacientes 0.681197 fármacos radiosensibilizadores 0.863769 biliary tract 0.652373 radical second operation 0.814041 Expandable metal stents 0.585727 estadio iv 0.572834	Cancer Facts 0.649725 surgical resection 0.561157 Shoup M 0.562495 Am Surg 0.635005 Cancer Staging Manual 0.913061 National Cancer Institute 0.633613 Surg Oncol 0.770159 from carcinoma 0.694816 PDQ Tratamiento 0.671094 New York 0.64622 second operation after 0.820352 tumor dissemination 0.618784 Physician Data Query 0.581575 Radiation therapy 0.568753 ganglios linfáticos n1 0.740227 Yoshida K 0.701223 estadio focal iia 0.6289 Byrd DR 0.659361 after simple cholecystectomy 0.807902 Tis Carcinoma 0.710719 Am Coll Surg 0.657212 T)a aReproducción 0.561453 AJCC Cancer Staging 0.929134 Edge SB 0.670645	CLICK HERE
1912	National Cancer Institute	Html	es	Tratamiento de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles.	síndromes mielodisplásicos.Quimioterapia 0.302945 linfocítica aguda 0.307126 siguientes procedimientos 0.33161 siguientes aspectos 0.303162 Neurofibromatosis tipo 0.303799 células madre formadoras 0.308269 siguientes especialistas 0.302945 hueso compacto 0.308024 neoplasias mieloides 0.310246 célula madre mieloide 0.324347 Bultos indoloros 0.302618 líquido cefalorraquídeo 0.326401 leucemia mielomonocítica 0.41887 Instituto Nacional 0.305639 célula madre linfoide 0.318549 siguientes problemas 0.302781 leucemia mielógena 0.419565 neoplasias mielodisplásicas 0.302899 LMA recién 0.316713 cáncer regrese).El 0.307025 madre mieloides 0.328575 células madre mieloides 0.318746 leucemia promielocítica aguda 0.371662 células madre 0.977959 leucemia mielógena aguda 0.321693	leucemia aguda 0.310888 leucemia linfoblástica aguda 0.335277 síndromes mielodisplásicos 0.43219 enlace drugs approved 0.308769 Acute Myeloid Leukemia 0.309058 infantil recidivante 0.30755 Sudores nocturnos 0.302372 efectos tardíos 0.309904 médula ósea.Leucemia mielógena 0.31318 células cancerosas.El gemtuzumab 0.309349 punción espinal.Ampliar 0.30255 leucemia granulocítica aguda 0.320187 PDQ Tratamiento 0.305949 blastocitos mieloides 0.303489 tirosina cinasa 0.339619 sistema nervioso central 0.381371 leucemia mieloblástica aguda 0.320188 Physician Data Query 0.305829 enfermedades mieloides 0.315553 SMD)Algunos tratamientos 0.302284 revés.La prueba 0.301997 leucemia mieloide aguda 0.981978 célula madre 0.354129 siguientes sumarios 0.305018	CLICK HERE
1943	National Cancer Institute	Html	es	Síndromes cardiopulmonares (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las afecciones comunes que producen síntomas en el tórax. Los síndromes cardiopulmonares que se exponen en este sumario son la disnea relacionada con el cáncer, el derrame pleural maligno, el derrame pericárdico y el síndrome de la vena cava superior.	pleural catheter 0.17861 Ripamonti C 0.130559 dificultad respiratoria 0.26023 malignant effusion 0.115362 lung cancer 0.190962 Sin embargo 0.114284 end-of-life patients with 0.119385 indwelling pleural catheter 0.162022 Dudgeon DJ 0.13043 fármacos pleurales esclerosantes 0.112004 disfunción muscular respiratoria 0.121219 Hematol Oncol Clin 0.143013 hypoxemic patients with 0.118489 patients receiving chemotherapy 0.111162 Cancer Organisation Thoracic 0.117844 antitusivos opioides 0.112496 recurrent symptomatic malignant 0.110714 patients with 0.625852 insuficiencia cardiaca 0.134239 Pain Symptom Manage 0.478956 randomized controlled 0.112081 pleural fluid 0.136904 Cancer Dyspnea Scale 0.146703 Moroni M 0.110841 Care Cancer 0.128094	pleural catheter vs 0.135869 Physiol Neurobiol 0.116436 as symptomatic treatment 0.110943 derrame maligno fracasa 0.114534 obstructiva crónica 0.135859 vías respiratorias 0.205286 tunnelled pleural catheter 0.139919 tos crónica causa 0.111919 prospective randomized 0.110614 pleural effusions with 0.149859 Intern Med 0.132242 Clin Oncol 0.11762 Med Pediatr Oncol 0.111608 Clin North Am 0.136363 Bruera E 0.203018 systematic review 0.116364 Oncol Clin North 0.140711 American Thoracic Society 0.114142 as palliative treatment 0.110799 malignant pleural effusions 0.900896 Crit Care Med 0.171232 symptomatic malignant 0.122652 alone versus 0.11566 compared with 0.110951	CLICK HERE
2070	National Cancer Institute	Html	es	Inhibidores de la angiogénesis	Hoja informativa que describe el proceso de eliminación de suministro de sangre a los tumores. Incluye una lista de los cánceres en los que se está probando este enfoque.	vasos sanguíneos resultantes 0.32417 NCI de estudios 0.304711 llamadas metástasis 0.305878 posibles efectos 0.304824 Drug Administration 0.306756	células renales 0.307581 angiogénesis efectos 0.326284 Estados Unidos 0.315596 vasos sanguíneos 0.986577	CLICK HERE
16146	National Cancer Institute	Html	es	Virus de la enfermedad de Newcastle (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del virus de la enfermedad de Newcastle (VEN) como tratamiento para las personas con cáncer.	tumor cell immunogenicity 0.407212 Cancer Res Clin 0.40874 active specific immunotherapy 0.409234 abstract from 0.408151 with newcastle 0.446575 with virus-modified 0.40752 oncolytic virus 0.412098 Reichard KW 0.412175 with virally modified 0.408993 treated postsurgically with 0.409032 Cancer Res 0.456074 Schirrmacher V 0.472403 Csatary LK 0.410713 virus selectively kills 0.408217 Natl Cancer Inst 0.453624 human tumor 0.419154 immunotherapy with 0.411294 Attenuated veterinary virus 0.408258 Ahlert T 0.417009 patients with 0.422834 autologous tumor cells 0.443634 immunotherapy with virally 0.409777 immunization with 0.407432 Lorence RM 0.416992 modified autologous tumor 0.409356	newcastle disease virus 0.990705 virus infeccioso destrucción 0.419778 Lítica Virus 0.418733 virus as 0.414895 tumor cell modification 0.407198 tumor cells 0.594311 virus therapy 0.428512 specific immunotherapy 0.411581 postsurgically with newcastle 0.414603 Cassel WA 0.412481 tumor vaccines 0.414853 Clin Oncol 0.407495 patient with 0.407334 virus mutant with 0.411813 after local newcastle 0.411338 postoperative immunotherapy with 0.409993 malignant melanoma patients 0.409365 with tumor cells 0.411774 renal cell carcinoma 0.40842 malignant melanoma 0.414222 tumor necrosis 0.410434 in vitro 0.430542 virus is reviving 0.408425 active specific 0.412889	CLICK HERE
16680	National Cancer Institute	Html	en	Cancer Moonshot℠ Implementation	Implementation teams are considering multiple ways to fund new programs as well as expansions of ongoing efforts to advance the goals of the Cancer Moonshot.	Cancer Moonshot-related research 0.688251 ongoing efforts 0.579887 funding opportunity announcements 0.69197 authorization 0.517804 oversight 0.515337 Cancer Moonshot portfolio 0.716496 academia 0.515431 Cancer Moonshot goals 0.684682 Century Cures Act 0.85793 expansions 0.51624 implementation teams 0.716347 email Partnerships_CancerMoonshot 0.582993 list 0.516345 Scientific Advisors 0.584259 important role 0.585193 longer-term scientific initiatives 0.700429 research opportunities 0.75591 multiple ways 0.591922 private sector 0.587499 Cancer Moonshot 0.987984 Cancer Moonshot initiatives 0.68956 concept proposals 0.656557 automatic email 0.583279 receipt 0.519207	NCI intramural staff 0.745934 cancer research community 0.682183 NCI extramural program 0.749793 Program Leadership Committee 0.655079 potential partners 0.586537 available FOAs 0.62206 NCI’s Board 0.674346 NIH institutes 0.582819 existing funds 0.59672 new research opportunities 0.683581 21st Century Cures 0.861565 scientific opportunities 0.594628 Blue Ribbon Panel 0.846596 BRP recommendation 0.740701 working groups 0.588634 new funding concepts 0.653803 BRP recommendations 0.654047 Public-private partnerships 0.590589 Cancer Moonshot implementation 0.678145 NCI advisory committees 0.753041 NCI’s Scientific 0.67691 report 0.517155 new programs 0.586358 funding mechanism 0.587953	CLICK HERE
16708	National Cancer Institute	Html	en	ALCHEMIST (The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): Questions and Answers	ALCHEMIST represents three integrated, precision medicine trials that are designed to identify people with early-stage lung cancer who have tumors that harbor certain uncommon genetic changes and evaluate whether drug treatments targeted against those mol	certain genetic alterations 0.511031 ALK gene rearrangement 0.86792 specific genetic alterations 0.510493 lung cancer 0.965003 ALK genetic alterations 0.561732 component trials 0.510228 National Clinical Trials 0.497396 clinical trials 0.62346 early-stage lung cancer 0.707269 EGFR gene mutation 0.628828 best treatment approach 0.483241 lung cancers 0.649896 ALK Treatment component 0.564764 ECOG-ACRIN Cancer Research 0.536673 ALK rearrangement 0.515701 non-small cell lung 0.519586 Adjuvant Lung Cancer 0.554841 EGFR gene mutations 0.510846 uncommon genetic changes 0.484048 ALCHEMIST treatment trial 0.613717 new treatment approaches 0.481108 lung carcinoid tumors 0.539366 early-stage lung cancers 0.57159 appropriate ALCHEMIST treatment 0.663904	ALK gene 0.888431 precision medicine trials 0.560161 tumor tissue 0.58358 United States 0.513049 Dana-Farber Cancer Institute 0.495276 ALK alterations 0.531283 small cell lung 0.519071 National Cancer Institute 0.484824 ALCHEMIST study 0.594796 cancer risk characteristics 0.487226 EGFR Treatment component 0.512344 participants 0.568322 ALCHEMIST treatment trials 0.868218 genetic alterations 0.637424 complete surgical removal 0.527484 Cancer Research Group 0.536403 early-stage lung adenocarcinoma 0.54246 cell lung cancer 0.575738 Cancer Genomics 0.482098 FDA-approved Vysis ALK 0.52631 ALCHEMIST screening trial 0.716569 ALCHEMIST trials 0.680442 standard therapy 0.505511 Clinical Trials Agreement 0.491455	CLICK HERE
17279	National Cancer Institute	Html	es	Planes para atender un cáncer avanzado	Una planificación cuidadosa reducirá el peso que enfrentará su familia más adelante. La planificación puede incluir aspectos económicos y legales, pero como verá, también puede ser una forma de celebrar su vida y de darle significado.	tensiones. Algunas personas 0.876955		CLICK HERE